FDA Expands Eligibility for Cancer Clinical Trials

The U.S. Food and Drug Administration has finalized new guidance aimed at broadening eligibility criteria for cancer clinical trials. This update addresses factors like performance status, washout periods, and concomitant medications, seeking to make trials more inclusive. The goal is to better represent real-world patient populations, potentially accelerating drug development and improving treatment access.